ABPT in Secondary Pneumothorax With Persistent Airleak Study
Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 17, 2019
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
The patient must have a chest tube in place and checked to be patent. Approximately 1.5ml/kg of venous blood will be withdrawn from the patient and immediately instilled it into the pleural cavity with aseptic technique via the chest tube already in situ. (There is no standard amount of blood used for ABPT. A small randomized study advocated that the use of 1.5ml/kg as it provided the optimal benefits.) The drain is then flushed with 20ml normal saline to avoid clotting. The tube of the drain is immediately elevated to 60cm above the insertion point of the chest tube at the patient's chest ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18 years or older;
- • radiographically proven pneumothorax and underlying lung disease (either pre-existing or shown in diagnostic imaging at presentation);
- • chest tube inserted which still shows an air leak at day 5 (or later) after the first radiographic evidence of a pneumothorax.
- Exclusion Criteria:
- • inability to provide informed consent;
- • a chest tube smaller than 12 F (because of the risk of blockage by blood)
- • bilateral pneumothorax
- • uncorrectable coagulopathy
- • active or recent (within 6 weeks) pleural infection
- • use of long term steroid or immunosuppressant
- • septicaemia or active extrapleural infection (eg pneumonia)
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Chun Li Dr Ngai
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials